We found that co-treatment with MA and osimertinib in lung cancer cells significantly inhibited the expression of FTH1 compared with the osimertinib alone treatment group, which further activated the ferroptosis pathway and enhanced EGFR-TKI sensitivity. The gene discussed is EGFR; the disease is lung carcinoma.